SCHEMBL24617348

SCHEMBL24617348

CNC(=O)c1cccc(Cn2ccc3cc(-c4cn[nH]c4C(F)(F)F)cnc3c2=O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 2/20 0.42
TDO2 P48775 1/20 0.41
YTHDC1 Q96MU7 1/20 0.41
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.38
ROCK2 O75116 1/20 0.37
ROCK1 Q13464 1/20 0.37
HTT P42858 1/20 0.37
CDK8 P49336 1/20 0.37
WNT1 P04628 1/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
GRK2 P25098 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36
GLO1 Q04760 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.35
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29135975 0.88 ROCK2 (0.49) KDM4ESMN1; SMN2ALDH1A1TDO2YTHDC1
SCHEMBL29778579 0.88 ROCK2 (0.49) KDM4ESMN1; SMN2ALDH1A1TDO2YTHDC1
SCHEMBL24617437 0.84 TDO2 (0.43) KDM4ESMN1; SMN2ALDH1A1TDO2YTHDC1
SCHEMBL24617341 0.79 YTHDC1 (0.43) KDM4ESMN1; SMN2ALDH1A1YTHDC1MAPK1
SCHEMBL29136007 0.79 ROCK1 (0.48) TDO2YTHDC1MAPK1ROCK2ROCK1
SCHEMBL24617619 0.77 ROCK2 (0.41) KDM4ESMN1; SMN2ALDH1A1TDO2MAPK1
SCHEMBL29135935 0.77 TDO2 (0.42) KDM4ESMN1; SMN2ALDH1A1TDO2YTHDC1
SCHEMBL24617616 0.77 MAPK1 (0.40) KDM4ESMN1; SMN2ALDH1A1TDO2MAPK1
SCHEMBL29778506 0.77 TDO2 (0.42) KDM4ESMN1; SMN2ALDH1A1TDO2YTHDC1
SCHEMBL24616945 0.77 ROCK2 (0.51) KDM4ESMN1; SMN2ALDH1A1TDO2YTHDC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 US claimed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 CN claimed
EP-4274825-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2023-11-15 EP claimed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 WO claimed
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 US disclosed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 CN disclosed
EP-4274825-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2023-11-15 EP disclosed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 WO disclosed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF ROCK2, ROCK1, MYLK3 KDM4E 1545/4885SMN1; SMN2 2301/4885ALDH1A1 4655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.